Media enquiries
Thank you for your message!
We will examine it with utmost attention and get back to you shortly.
Do you have
any question?
Saint-Cloud and Paris – January 19, 2021 – Ethypharm and ORPHELIA Pharma announce today the signature of an exclusive agreement for the development, registration and marketing in the People’s Republic of China of Kigabeq® (vigabatrin) indicated for the first-line treatment of infantile spasms (West syndrome).
Thank you for your message!
We will examine it with utmost attention and get back to you shortly.